Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Elpiscience’s $100M series B provides path to IPO

Hongjiang Li, Staff Writer
December 28, 2019 2:01 AM UTC

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of global BD, told BioCentury.

New investors Tencent, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont and Parkway Global invested in the round, as did existing investors Lilly Asia Ventures (LAV), Hillhouse Capital Group and CDH Investments. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Elpiscience Biopharmaceuticals Inc.